Medicines (MDCO) Posts Q3 Loss of $0.06
More News related to MDCO
- Medicines Co. (MDCO) Releases Phase III Data for CHAMPION Program of Cangrelor
- The Medicines Company's Full Analysis of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patient Outcomes Following PCI
- Cleviprex Results Reported From Study in Patients With Intracerebral Hemorrhage
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Medicines (MDCO) Posts Q3 Loss of $0.06
More News related to Earnings
- RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
- Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
The Medicines Company (NASDAQ: MDCO) reports Q3 EPS of $0.06, versus the analyst estimate of ($0.05). Revenue for the quarter was $98.80 million, which compares to the estimate of $96.99 million.
Related Categories
EarningsStocks Mentioned
+0.48Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
